Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study
Authors:
Open Access
- 3 January 2026
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 61 (4) , 398-409
Abstract
Background: Very-early-onset inflammatory bowel disease (VEO-IBD), representing cases diagnosed before age 6 years, is increasing in prevalence. Although VEO-IBD often presents as severe, treatment-resistant disease requiring biologic agents, studies showing the effectiveness of biologics, such as ustekinumab (UST) and vedolizumab (VDZ), remain limited. Methods: We retrospectively analyzed patients with VEO-IBD treated for at least a year from 13 institutions in Japan, evaluating clinical course including effectiveness of biologics, such as infliximab (IFX), adalimumab (ADL), UST, and VDZ. Patients with monogenic IBD were excluded. Steroid-free clinical remission (SFCR) and treatment persistence were assessed separately for first-line and for second-line or subsequent biologic therapies. Results: We studied 101 VEO-IBD patients (56% male; median age, 3.6 years), including 40 with Crohn’s disease, 52 with ulcerative colitis, and 9 with unclassified IBD. Biologics were used in 67 patients, most commonly infliximab (IFX; n = 52), followed by UST ( n = 38), adalimumab (ADL; n = 23), and VDZ ( n = 21). As first-line therapy, IFX and ADL achieved 1-year SFCR rates of 19% and 46%, with persistence rates of 36% and 48%. Despite being used mainly as second-line or subsequent therapies, UST and VDZ showed 1-year SFCR rates of about 45% and 36%, and maintained persistence of 79% and 46%, respectively, with UST demonstrating higher persistence than TNF-α inhibitors ( P < 0.01). No discontinuations due to infusion reactions or other adverse events occurred with UST or VDZ. Conclusion: UST and VDZ were effective and well tolerated even when used as second-line or subsequent therapies for VEO-IBD.Keywords
This publication has 41 references indexed in Scilit:
- Evolving Trends in Pediatric Inflammatory Bowel Disease Management in Japan: A Decade of Nationwide DataJGH Open, 2025
- Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter studyJournal of Pediatric Gastroenterology and Nutrition, 2024
- Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension resultsJournal of Pediatric Gastroenterology and Nutrition, 2024
- Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHANPediatric Drugs, 2024
- Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN StudyClinical Gastroenterology and Hepatology, 2022
- A Systematic Review of Monogenic Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2022
- Infliximab in young paediatric IBD patients: it is all about the dosingEuropean Journal of Pediatrics, 2020
- Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2019
- Mathematical weighting of the pediatric Crohnʼs disease activity index (PCDAI) and comparison with its other short versionsInflammatory Bowel Diseases, 2012
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011